TargetRX - Know How.

New Tool Analyzes Physician Behaviors and Attitudes around Co-Pay Card Programs; Provides Insights to Increase Usage and Maximize Marketing Investment

Horsham, Pa. - November 30, 2009 - Companies marketing branded pharmaceuticals are facing an increasing need to make products more accessible and affordable for patients. Furthermore, the rise of competition among branded drugs has led many pharmaceutical companies to focus less on DTC spending and more on increased investment in co-pay card programs in order to make these treatments more cost-effective for patients. In response to this market demand, TargetRx today announced a new offering that enables pharmaceutical companies to understand how physicians perceive these programs and how they impact prescribing behavior - information that is critical to achieving increased patient adoption and maximizing return on investment for these programs.

Industry Leaders from IMS & Verispan Join TargetRx to Field Increasing Demand for Pharma & Biotech Sales & Marketing Solutions

Horsham, Pa. - September 14, 2009 - With a 25 percent increase in year over year revenue and a growing portfolio of pharmaceutical and biotech clients, TargetRx today announced the addition of Dave Dornstreich as vice president of business development and David Deutsch as vice president of client service and development. Each executive will play a key role in supporting the expansion of TargetRx's customer base and leading the development of new pharmaceutical sales and marketing effectiveness solutions.

Uncovers the Most Effective Personal Promotion Strategies and Tactics by Isolating the Impact of Promotion from Other Influencers of Prescribing

Horsham, Pa. - February 2, 2009 - Getting pharmaceutical sales forces to be highly efficient and effective has always been challenging, but the complexity created by the increasing roles of payors, patients, and industry regulations has made it more difficult than ever. Today, pharmaceutical companies can no longer rely on the traditional "activity-oriented" data that was used to create and sustain the old commercial model. As a result, TargetRx has released FieldPerformanceAdvantage to help pharmaceutical and biotech companies understand how in-field sales and marketing initiatives are actually performing at driving prescribing and how to quickly improve these initiatives as the market continues to undergo rapid change.